Microsoft and medical imaging solutions and service provider for image interpretation and management in oncology, MEDIAN Technologies, are collaborating to develop new cancer detection, diagnosis and monitoring methods using Big Data analytics.
As part of the initiative, MEDIAN Technologies will install its imaging biomarker phenotyping system (IBIOPSY™) on the Microsoft Azure cloud computing platform.
On Azure, IBIOPSY™ will provide capabilities for processing and analysing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes.
“Precision Medicine is about to revolutionise how diagnostic and biological data is used to pinpoint and deliver care that is preventive, targeted and effective,” said CEO at MEDIAN Technologies, Fredrik Brag.
“Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort. Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments. Our collaboration with Microsoft will allow us to deliver these solutions into routine clinical practice on a global scale on the Azure Cloud Computing platform,” continued Brag.
“Microsoft Innovation teams are committed to providing their technical expertise to health professionals who use medical images in their daily routine. We are proud to collaborate with MEDIAN on the IBIOPSY™ project and to bring innovative technologies at the service of cancer research”, said Chief Technology & Security Officer at Microsoft France, Bernard Ourghanlian.
“Indeed, we are, more than ever committed to addressing the biggest challenges in cancer detection, diagnosis and monitoring, by offering access to the latest and most innovative technologies. By taking advantage of the powerful Microsoft Azure cloud platform, IBIOPSY™ will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring,” continued Ourghanlian.
IBIOPSY™ will eventually be made available to medical facilities and physicians in the US, Europe and Asia to meet the image processing and data analytics needs created by the next generation of personalised cancer therapies and the growth in medical imaging data.
MEDIAN Technologies and Microsoft future collaboration will focus on the development of novel predictive analytics methods based on machine learning and encryption capabilities that will be available on Azure.